We are thrilled to announce that starting from Oct 2019 our company will participate in PAVE, a challenging project that aims to develop novel vaccine approaches, including use of multiple immunomodulating components for treatment of pancreatic cancer.

vaccine pancreaticcancer h2020 msca cancertherapy

Click here to learn more about PAVE!

Leave a Reply

Your email address will not be published. Required fields are marked *